Replies to post #1317 on RespireRx Pharmaceuticals Inc (RSPI)

[Aiming4]

I agree with everything you wrote GFP, with the following possible additions:

1. It would not surprise me to see a financing occur on the same date the clinical hold is released. I believe Cortex has formerly timed financings concurrently with positive news. Such a financing deal might already be in place and if so, we'll continue to see small but steady price erosion right up to the date the FDA decision is announced.

2. Based on investors expecting a financing at some point and the pps machinations that usually go along with a financing, I'm not expecting to see $5 after the clinical hold is released.

History has taught me that something usually holds COR's price back more than expected, even when good news is announced. Admittedly COR climbing to $5+ after the ADHD results broke that pattern, but I think it's more likely the pps after the FDA decision (assuming it's positive) will be underwhelming rather than overwhelming.

I won't be upset if I'm mistaken though... Aiming4.

[ampakineman]

Gfp,

You said:
"A seriously bad finding in the new studies, and CX-717 is toast. This is very unlikely, and we would have probably already heard something from Cortex".

Such a serious result should definitely have been identified by COR during the tests, thus the data would not have been submitted to the FDA. (Why would they?) Stranger things have happened I know, but if bad findings are uncovered in the submitted data then Stoll & company haven't been doing their job! I don't think this is anywhere near to being true!

My suspicion is that we're clean, but the FDA will take every milisecond of the thirty days. It's a show of power for a beaurocracy that has been under the gun for quite a while.

I predict the stockprice will be %$6.00/share by mid October, regardless of PIPE or any other associated shenanigans.